Provided by Tiger Trade Technology Pte. Ltd.

ADVANCED HEALTH INTELLIGENCE LTD SPON ADS EACH REP 7 ORD SHS

1.50
0.0000
Volume:- -
Turnover:- -
Market Cap:14.76M
PE:-0.96
High:1.50
Open:1.50
Low:1.50
Close:1.50
52wk High:1.50
52wk Low:1.50
Shares:9.84M
Float Shares:6.39M
Volume Ratio:1.14
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5660
EPS(LYR):-1.2933
ROE:-156.27%
ROA:-46.98%
PB:12.01
PE(LYR):-1.16

Loading ...

Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026

GlobeNewswire
·
Jan 14

Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

GlobeNewswire
·
Dec 13, 2025

Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)

GlobeNewswire
·
Dec 03, 2025

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

GlobeNewswire
·
Nov 08, 2025

Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus

GlobeNewswire
·
Oct 30, 2025

Advanced Health Intelligence Ltd Delisted from ASX

TIPRANKS
·
Oct 01, 2025

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

GlobeNewswire
·
Sep 30, 2025

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

GlobeNewswire
·
Sep 30, 2025

Director Scott Montgomery Departs Advanced Health Intelligence

TIPRANKS
·
Sep 16, 2025

Advanced Health Intelligence Appoints Dylan Garnett as CEO to Drive Growth

TIPRANKS
·
Sep 16, 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

GlobeNewswire
·
Aug 11, 2025

Nyxoah Gets FDA Approval for Genio Sleep Apnea Device; Shares Rise After Hours

MT Newswires Live
·
Aug 09, 2025

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

GlobeNewswire
·
Aug 08, 2025

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

GlobeNewswire
·
Jul 30, 2025

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine

GlobeNewswire
·
Jul 29, 2025